Catalog: 101327

Lot: 211222

Product Information

Description:

This monoclonal antibody recognizes the SARS-CoV-2 Spike (B.1.1.529, Omicron Variant) RBD Domain and the S1+S2 trimeric complex to neutralize its interaction with ACE2 [Table of variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. This neutralizing antibody has been functionally tested using the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant):ACE2 Inhibitor Screening Colorimetric Assay Kit (BPS Bioscience #78339).

Concentration: 0.5 mg/ml

Specificity: The antibody recognizes the B.1.1.529 Omicron variant RBD domain and the

S1+S2 trimeric protein. It has not been tested on other spike variants, or on

the S1 subunit.

Formulated In: 1X PBS, 0.2% BSA

Purification: Protein A affinity chromatography

Format: Aqueous buffer solution

Storage: Store in aliquots at -20°C. Stable for at least 6 months from date of receipt.

Avoid freeze/thaw cycles.

MW: ~150 kDa

Assay Conditions: The functional activity of the antibody was measured using "SARS-CoV-2 Spike

RBD (B.1.1.529, Omicron Variant): ACE2 Inhibitor Screening Colorimetric Assay

Kit" (BPS Bioscience #78339). Experimental Design:

1. A flat bottom clear 96-well plate was coated with 50 μ l of spike RBD protein (1 μ g/ml diluted in PBS) and incubated overnight at 4°C.

- 2. The next day, the plate was washed three times with 1 x Immuno Buffer 1 and blocked with 100 μ l of blocking buffer for 1 hour at room temperature with slow shaking.
- 3. The spike protein was preincubated with 50 μ l of neutralizing antibody (using serial three-fold dilutions in duplicates, ranging from 200 nM to 0 nM). The neutralizing antibody was diluted in blocking buffer, 50 μ l of diluted antibody was added to the plate and incubated for 30 minutes at room temperature with slow shaking. For the wells labeled "blank" and "positive control", 50 μ l of blocking buffer was added instead of diluted antibody.
- 4. ACE2-biotin (BPS Bioscience #100665) was diluted to 1.5 ng/ μ l in blocking buffer and 50 μ l was added to the wells containing spike protein and neutralizing antibody. 50 μ l of blocking buffer was added to the "blank" instead of ACE2-Biotin. The plate was incubated for 1 hour at room temperature with slow shaking.
- 5. The wells were washed 3 times with $1 \times 1 = 100$ MeV and $1 \times 1 = 100$ MeV. Streptavidin (BPS Bioscience #79742) diluted in blocking buffer was added to all wells for 30 minutes at room temperature with slow shaking.
- 6. The wells were washed 3 times before addition of 100 μ l of Colorimetric HRP Substrate (BPS Bioscience #79651) to all wells.



Catalog: 101327

Lot: 211222


7. The reaction was quenched with an equal volume (100 μ l) of 1N HCl. 8. Absorbance was read at 450 nm. The "blank" value was subtracted from all other measurements.

Applications:

This product is for research use only. It is not suitable for human, diagnostic or therapeutic use. The monoclonal neutralizing IgG can be used for functional assays to block SARS-CoV-2 Spike protein and ACE2 binding.

Quality Control Data

Neutralization of SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant)



Clone G10xA5 neutralizing antibody competes with and blocks the binding of ACE2-biotin Omicron B.1.1.529 Variant spike protein. The IC50 of Spike protein: ACE2 neutralization is determined at various concentrations of the neutralizing antibody (200 nm to 0 nm, three-fold dilutions) following the assay conditions described above.



Catalog: 101327

Lot: 211222

Related Products

Products	Catalog #	Size
Spike S1 Neutralizing Antibody (Clone G10xA5) (SARS-CoV-2)	101327	100 μg
Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2):ACE2 Inhibitor Screening Colorimetric Assay Kit	78339	96 reactions
Spike S1 RBD (B.1.1.529, Omicron Variant), Avi-His-Tag (SARS-CoV-2)	101316	100 μg
Spike S1 RBD (B.1.1.529, Omicron Variant), Avi-His-Tag, Biotin- Labeled (SARS-CoV-2)	101317	25 μg/50 μg
Spike S1 Neutralizing Antibody (Clone C-A11) (SARS-CoV-2)	101024	100 μg
Spike Trimer Neutralizing Antibody (Clone hC-A11) (SARS-CoV-2)	101061	100 μg
ACE2, His-Avi-Tag, Biotin-labeled HiP™	100665	20 μg/50 μg
Spike S1 RBD, Avi-His-tag (SARS-CoV-2)	100696	100 μg/1 mg
Spike RBD (B.1.1.7 Variant), Avi-His-Tag (SARS-CoV-2)	100977	100 μg/1 mg
Spike Trimer (S1+S2), His-tag (SARS-CoV-2)	100728	100 μg/1 mg
Spike Trimer (S1+S2) (B.1.1.7 Variant), His-Tag (SARS-CoV-2)	510334	100 μg/1 mg
Spike S1 RBD (B.1.617.2, Delta Variant), Avi-His-Tag (SARS-CoV-2)	101153	100 μg/1 mg
Spike Trimer (S1+S2) (P.1 Variant), His-Tag (SARS-CoV-2)	100989	100 μg/1 mg
Spike Trimer (S1+S2) (B.1.617.2; Delta Variant), His-Tag (SARS-CoV-2)	101147	100 μg
Spike Trimer (S1+S2) (B.1.617.2.1, Delta Plus Variant), His-Tag (SARS-CoV-2)	101165	100 μg
SARS-CoV-2 Spike Trimer (S1+S2):ACE2 Inhibitor Screening Colorimetric Assay Kit	79999	96 reactions

